Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

Toshinari YamashitaJoo Hyuk SohnEriko TokunagaNaoki NiikuraYeon Hee ParkKeun Seok LeeYee Soo ChaeBinghe XuXiaojia WangSeock-Ah ImWei LiYen-Shen LuCecilia Orbegoso AguilarSoichiro NishijimaYuji NishiyamaMasahiro SugiharaShanu ModiJunji Tsurutani

Published in: Breast cancer (Tokyo, Japan) (2024)

ClinicalTrials.gov, NCT03734029.

Keyphrases

metastatic breast cancer
emergency department
locally advanced
randomized controlled trial
squamous cell carcinoma
combination therapy
replacement therapy
phase iii